Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
19 hedge funds and large institutions have $17.3M invested in Apexigen, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.17M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
+$3M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$2M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.4M |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$1.32M |
Top Sellers
APGN Hedge Fund Activity: Q1 2021 in Review
19 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q1 2021, worth a combined $17.3M.
Buyers outnumbered sellers: 19 funds opened new APGN positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Periscope Capital, opening a new position worth an estimated $4.17M.
- 19 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $17.3M of Apexigen, Inc. Common Stock stock for Q1 2021.
- 19 funds opened new Apexigen, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +19 holders.
- The largest Apexigen, Inc. Common Stock buyer in Q1 2021 was Periscope Capital, an estimated $4.17M added.
Based on aggregated 13F filings for Q1 2021.